Loading people...
Chris Garabedian is the Chairman and Chief Executive Officer of Xontogeny and a Portfolio Manager at Perceptive Advisors in Boston, Massachusetts. In his venture capital role, he manages the Perceptive Xontogeny Venture Funds, which have raised over $1 billion in aggregate capital, including the $515 million PXV Fund III closed in May 2024. Previously, he served as President and CEO of Sarepta Therapeutics from 2011 to 2015, where he directed the company's turnaround and Duchenne muscular dystrophy program to achieve a multi-billion dollar valuation. His earlier biopharmaceutical career includes leading corporate strategy at Celgene and holding global commercial and corporate development executive positions at Gilead Sciences and Abbott Laboratories. Garabedian currently focuses on accelerating early-stage life sciences, medtech, and biotechnology ventures through seed and Series A investments ranging from $500,000 to $20 million.
Chris Garabedian stands out as a highly influential figure in the life sciences investment landscape, known for his unique blend of operational expertise and strategic investment acumen. As the CEO of Perceptive Xcellerator, an integral part of Perceptive Advisors, he spearheads the incubation and acceleration of groundbreaking early-stage biotechnology companies. In addition to this leadership role, Mr. Garabedian is a Portfolio Manager for Perceptive Advisors' private equity and venture capital funds, actively shaping the firm's investment strategy in the dynamic healthcare sector.
Perceptive Advisors is a leading investment firm dedicated to the healthcare and life sciences industries. Under Chris Garabedian's guidance, the firm's investment focus areas are primarily innovative drug discovery and development platforms, novel therapeutic modalities, and companies addressing significant unmet medical needs. He is particularly adept at identifying promising biotech ventures that possess strong scientific foundations and clear pathways to clinical and commercial success. His approach often involves hands-on engagement with portfolio companies, leveraging his extensive operational background to guide their growth and development.
Garabedian's career background is marked by significant leadership roles in the biotechnology industry. Prior to joining Perceptive Advisors, he served as the President and CEO of Sarepta Therapeutics, where he is widely credited with orchestrating a remarkable turnaround. During his tenure at Sarepta, he led the company through critical stages of development, including the advancement of treatments for Duchenne muscular dystrophy, ultimately transforming it into a leading gene therapy company. Before Sarepta, he held senior executive positions at major pharmaceutical and biotech firms, including Genzyme (now Sanofi Genzyme) and Celgene (now Bristol Myers Squibb), where he gained invaluable experience in drug development, commercialization, and corporate strategy.
His notable involvement extends beyond Sarepta, encompassing a range of strategic investments and board positions in emerging biotech companies. Through Perceptive Xcellerator, he has been instrumental in fostering a new generation of life sciences innovators, providing not just capital but also crucial strategic guidance and operational support. Chris Garabedian's deep understanding of the scientific, clinical, and regulatory landscapes makes him a sought-after partner for entrepreneurs and a key driver of innovation in the biotech investment community.
Chris Garabedian is a prominent investor and executive in the life sciences sector. He is the CEO of Perceptive Xcellerator and a Portfolio Manager for Perceptive Advisors' private equity and venture capital funds, focusing on innovative biotech investments.
Chris Garabedian primarily invests in early-stage and high-growth life sciences and biotechnology companies. His focus areas include novel drug discovery and development platforms, therapeutic modalities, and companies addressing significant unmet medical needs within the healthcare industry.
Chris Garabedian works at Perceptive Advisors, a leading healthcare-focused investment firm. He holds the role of CEO of Perceptive Xcellerator and is a Portfolio Manager for the firm's private equity and venture capital funds.
